BioCentury
ARTICLE | Company News

Afferent, Merck deal

June 13, 2016 7:00 AM UTC

Merck will acquire Afferent for $500 million in cash and up to $750 million in clinical and commercialization milestones for candidates in Afferent’s pipeline, including AF-219. AF-219, a purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor antagonist, is in Phase IIb testing to treat refractory chronic cough and Phase II testing to treat idiopathic pulmonary fibrosis (IPF) with cough. The companies expect the deal to close next quarter. ...